Stock FHTX FOGHORN THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Foghorn Therapeutics Inc.

Equities

FHTX

US3441741077

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
5.49 USD +4.97% Intraday chart for Foghorn Therapeutics Inc. +3.58% -14.88%
Apr. 16 Foghorn Therapeutics Names Kristian Humer CFO MT
Apr. 16 Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
GL
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
GL
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
AQ
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
GL
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
GL
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
GL
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
AQ
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
GL
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
GL
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
AQ
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
GL
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
GL
Foghorn Therapeutics Announces CFO Departure
GL
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
GL
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
AQ
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
GL
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
AQ
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
GL
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
AQ
Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FHTX Stock
  4. News Foghorn Therapeutics Inc.
  5. Press Releases